TNF Pharmaceuticals, Inc. Cash Flow Conversion Efficiency
TNF Pharmaceuticals, Inc. cash flow conversion efficiency. Based on the latest financial reports, TNF Pharmaceuticals, Inc. (TNFA) has a cash flow conversion efficiency ratio of -0.178x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.07 Million) by net assets ($11.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of TNF Pharmaceuticals, Inc. (2004–2024)
Cash flow conversion efficiency of TNF Pharmaceuticals, Inc. from 2004 to 2024. This chart illustrates how TNF Pharmaceuticals, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for TNF Pharmaceuticals, Inc. for real-time trading data and today's change.
TNF Pharmaceuticals, Inc. Cash Flow Conversion Ratio Explained
TNF Pharmaceuticals, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
TNF Pharmaceuticals, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TNF Pharmaceuticals, Inc. ranked by their cash flow conversion efficiency. Also see TNF Pharmaceuticals, Inc. (TNFA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pharmacielo Ltd
V:PCLO
|
0.236x |
|
DGB Group NV
AS:DGB
|
0.235x |
|
Bell Copper Corp
V:BCU
|
-0.066x |
|
Compagnie des Eaux de Royan
PA:MLEDR
|
N/A |
|
Rockworth Public Company Limited
BK:ROCK
|
0.017x |
|
Gafisa S.A
SA:GFSA3
|
-0.084x |
|
Corella Resources Ltd
AU:CR9
|
-0.129x |
|
Micro Digital Co. Ltd
KQ:305090
|
-0.143x |
Annual Cash Flow Conversion Efficiency for TNF Pharmaceuticals, Inc. (2004–2024)
The table below shows the annual cash flow conversion efficiency of TNF Pharmaceuticals, Inc. from 2004 to 2024. Review TNFA cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.72 Million | $-8.98 Million | -0.610x | +39.99% |
| 2023-12-31 | $12.77 Million | $-12.98 Million | -1.016x | -21.70% |
| 2022-12-31 | $14.70 Million | $-12.27 Million | -0.835x | -1.17% |
| 2021-12-31 | $23.65 Million | $-19.52 Million | -0.825x | -511.96% |
| 2020-12-31 | $34.58 Million | $-4.66 Million | -0.135x | +58.96% |
| 2019-12-31 | $9.36 Million | $-3.07 Million | -0.329x | +77.49% |
| 2018-12-31 | $5.83 Million | $-8.52 Million | -1.460x | -117.05% |
| 2017-12-31 | $7.55 Million | $-5.08 Million | -0.673x | +45.40% |
| 2016-12-31 | $3.39 Million | $-4.17 Million | -1.232x | -58.49% |
| 2015-12-31 | $6.60 Million | $-5.13 Million | -0.777x | -196.31% |
| 2014-12-31 | $14.81 Million | $-3.88 Million | -0.262x | +60.39% |
| 2013-12-31 | $4.12 Million | $-2.73 Million | -0.662x | -173.81% |
| 2012-12-31 | $4.30 Million | $-1.04 Million | -0.242x | +34.04% |
| 2011-12-31 | $6.17 Million | $-2.26 Million | -0.367x | -36.69% |
| 2010-12-31 | $6.45 Million | $-1.73 Million | -0.268x | -39.14% |
| 2009-12-31 | $7.18 Million | $-1.38 Million | -0.193x | -522.17% |
| 2008-12-31 | $10.28 Million | $469.37K | 0.046x | +111.11% |
| 2007-12-31 | $-443.38K | $182.19K | -0.411x | -120.67% |
| 2006-12-31 | $-2.67 Million | $-5.31 Million | 1.988x | +210.63% |
| 2005-12-31 | $3.12 Million | $-5.61 Million | -1.797x | -222.55% |
| 2004-12-31 | $-2.79 Million | $-4.10 Million | 1.466x | -- |
About TNF Pharmaceuticals, Inc.
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rh… Read more